ESMO Highlights

flipper_slider

Editor's Choice

Dr Antonio Llombart-Cussac discusses data from the CASCADE study. FILMED AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING, OCTOBER 2016.

ESMO Highlights Videos

Coverage of the satellite symposium session "Emerging treatments for patients with cancer: practical guidelines and expert insights" presented at the European Society for Medical Oncology (ESMO) 2017 Congress on Monday 11 September 2017 in Madrid, Spain. The symposium was supported by Tesaro,...
Jean-Jacques Grob discusses the role of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the greatest controversies? 0:07 2. What is the...
Ivan Marquez Rodas discusses the unmet treatment needs in melanoma, and the benefits of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the...
Dirk Schadendorf discusses the unmet need and importance, benefits and timing of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the...
Mario Mandala discusses the importance, benefits and timing of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the greatest controversies? 0...
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss the issues with staging and the new staging guidelines at ESMO 2017. Support: The filming of this video was supported by Novartis.
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss “What evidence is there to allow comparison between the aggressiveness of BRAF-positive melanoma versus wild type and what does the evidence show?” at ESMO 2017. Support: The filming of this video was supported by Novartis.
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss "How do the short- and long-term benefit–risk balance issues for different treatment options with patients with metastatic BRAF-positive melanoma vary when discussing adjuvant treatment?" at ESMO 2017. Support: The filming of...
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss benefit–risk balance issues for different treatment options for patients with metastatic BRAF-positive melanoma. Support: The filming of this video was supported by Novartis.
Mario Mandala, Vanna Cahiarrion-Sileni and Jean-Jacques Grob discuss "How does the recently presented data on BRAK/MEK inhibitors and immunotherapy impact your choice of treatment for patients with BRAF-positive melanoma" at ESMO 2017. Support: The filming of this video was supported by Novartis.
Coverage of the Bayer supported satellite symposium "Radium-223 from bench to bedside and future directions for targeted alpha therapy " at TAT 2017. The video has been published on the touchONCOLOGY website with permission from Bayer.
Joe O'Sullivan discusses the role of radium-223 in the mestastatic prostate cancer treatment paradigm. Support: The filming of this video was supported by Bayer. Disclosures: Joe O'Sullivan has participated in Advisory Boards with Bayer, Sanofi and Janssen.
Dr Florian Scotte discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in French. Speaker disclosures: Consultant, speaker or advisory board with: Roche, Vifor, MSD, TEVA, Norgine, Prostrakan, Leo pharma, Janssen, Hospira, Boehringer, Sanofi, AMGEN, Pierre...
Dr Massimo Di Maio discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in Italian. Speaker disclosures: Received honoraria or acted as consultant for Bayer, Eli Lilly, AstraZeneca, Janssen, Bristol Myers Squibb, Merck Sharp...
Dr Pere Gascon discusses the role of rolapitant on chemotherapy-induced nausea and vomiting. Interview in Spanish. Filmed at the ESMO annual meeting, 2017